Compass Therapeutics (NASDAQ:CMPX) Upgraded to Hold at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, January 21st. Compass Point set a $10.00 price target on Compass Therapeutics in a report on Monday, October 6th. Raymond James Financial restated an “outperform” rating and issued a $9.00 price target on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Lifesci Capital assumed coverage on shares of Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 price objective on the stock. Finally, William Blair assumed coverage on shares of Compass Therapeutics in a report on Monday, January 5th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $12.23.

Compass Therapeutics Trading Up 0.3%

Shares of NASDAQ:CMPX opened at $6.40 on Friday. Compass Therapeutics has a 12-month low of $1.33 and a 12-month high of $6.49. The company has a market cap of $1.14 billion, a PE ratio of -14.22 and a beta of 1.45. The stock has a 50 day moving average of $5.46 and a 200 day moving average of $4.26.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Equities research analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its stake in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares in the last quarter. Creative Planning purchased a new position in shares of Compass Therapeutics in the 2nd quarter worth $30,000. Flagship Harbor Advisors LLC bought a new stake in shares of Compass Therapeutics in the 4th quarter worth about $32,000. Strs Ohio purchased a new stake in shares of Compass Therapeutics during the 1st quarter valued at about $34,000. Finally, Apollon Wealth Management LLC bought a new position in shares of Compass Therapeutics in the 3rd quarter valued at about $35,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.